TY - JOUR
T1 - Characterization of the antigenic heterogeneity of lipoarabinomannan, the major surface glycolipid of mycobacterium tuberculosis, and complexity of antibody specificities toward this antigen
AU - Choudhary, Alok
AU - Patel, Deendayal
AU - Honnen, William
AU - Lai, Zhong
AU - Prattipati, Raja Sekhar
AU - Zheng, Ruixiang Blake
AU - Hsueh, Ying Chao
AU - Gennaro, Maria Laura
AU - Lardizabal, Alfred
AU - Restrepo, Blanca I.
AU - Garcia-Viveros, Moncerrato
AU - Joe, Maju
AU - Bai, Yu
AU - Shen, Ke
AU - Sahloul, Kamar
AU - Spencer, John S.
AU - Chatterjee, Delphi
AU - Broger, Tobias
AU - Lowary, Todd L.
AU - Pinter, Abraham
N1 - Funding Information:
This work was supported by grants from the New Jersey Health Foundation, the Bill and Melinda Gates Foundation, and the Alberta Glycomics Centre.
Publisher Copyright:
Copyright © 2018 The Authors.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Lipoarabinomannan (LAM), the major antigenic glycolipid of Mycobacterium tuberculosis, is an important immunodiagnostic target for detecting tuberculosis (TB) infection in HIV-1–coinfected patients, and is believed to mediate a number of functions that promote infection and disease development. To probe the human humoral response against LAM during TB infection, several novel LAM-specific human mAbs were molecularly cloned from memory B cells isolated from infected patients and grown in vitro. The fine epitope specificities of these Abs, along with those of a panel of previously described murine and phage-derived LAM-specific mAbs, were mapped using binding assays against LAM Ags from several mycobacterial species and a panel of synthetic glycans and glycoconjugates that represented diverse carbohydrate structures present in LAM. Multiple reactivity patterns were seen that differed in their specificity for LAM from different species, as well as in their dependence on arabinofuranoside branching and nature of capping at the nonreducing termini. Competition studies with mAbs and soluble glycans further defined these epitope specificities and guided the design of highly sensitive immunodetection assays capable of detecting LAM in urine of TB patients, even in the absence of HIV-1 coinfection. These results highlighted the complexity of the antigenic structure of LAM and the diversity of the natural Ab response against this target. The information and novel reagents described in this study will allow further optimization of diagnostic assays for LAM and May facilitate the development of potential immunotherapeutic approaches to inhibit the functional activities of specific structural motifs in LAM. The Journal of Immunology, 2018, 200: 3053–3066.
AB - Lipoarabinomannan (LAM), the major antigenic glycolipid of Mycobacterium tuberculosis, is an important immunodiagnostic target for detecting tuberculosis (TB) infection in HIV-1–coinfected patients, and is believed to mediate a number of functions that promote infection and disease development. To probe the human humoral response against LAM during TB infection, several novel LAM-specific human mAbs were molecularly cloned from memory B cells isolated from infected patients and grown in vitro. The fine epitope specificities of these Abs, along with those of a panel of previously described murine and phage-derived LAM-specific mAbs, were mapped using binding assays against LAM Ags from several mycobacterial species and a panel of synthetic glycans and glycoconjugates that represented diverse carbohydrate structures present in LAM. Multiple reactivity patterns were seen that differed in their specificity for LAM from different species, as well as in their dependence on arabinofuranoside branching and nature of capping at the nonreducing termini. Competition studies with mAbs and soluble glycans further defined these epitope specificities and guided the design of highly sensitive immunodetection assays capable of detecting LAM in urine of TB patients, even in the absence of HIV-1 coinfection. These results highlighted the complexity of the antigenic structure of LAM and the diversity of the natural Ab response against this target. The information and novel reagents described in this study will allow further optimization of diagnostic assays for LAM and May facilitate the development of potential immunotherapeutic approaches to inhibit the functional activities of specific structural motifs in LAM. The Journal of Immunology, 2018, 200: 3053–3066.
UR - http://www.scopus.com/inward/record.url?scp=85046298025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046298025&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1701673
DO - 10.4049/jimmunol.1701673
M3 - Article
C2 - 29610143
AN - SCOPUS:85046298025
SN - 0022-1767
VL - 200
SP - 3053
EP - 3066
JO - Journal of Immunology
JF - Journal of Immunology
IS - 9
ER -